Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
View Full Paper
Ask AI
Bookmark
Share
Key result
Stage III breast cancer linked to ~22% higher circulating PCSK9 levels versus benign breast lesions.
- P<0.05
- n=46
Why the study?
Little is known about the role of circulating lipid-related factors such as PCSK9, ANGPTL3, and lipoprotein (a) in cancers.
Comparison
Stage III breast cancer vs premalignant (stage 0, n = 9) or benign (n = 14) breast lesions
Design
Age-matched case-control study
Authors
Discussion
Loading...
Member takes
Implication
PCSK9 elevation should not change breast cancer management; leaves open a progression link needing prospective validation.
Study Design
Type
Case-Control (n=46)
Multicenter
No
Structured PICO
P
Population
46 women aged 36 years or older, including 23 with stage III breast cancer (ductal, lobular, or mixed) and 23 age-matched controls with benign breast disease (n=14) or stage 0 breast cancer (n=9).
O
Outcome
Circulating levels of PCSK9, ANGPTL3, and Lp(a)surrogate
Main Result
Absolute Event Rate: 95.9% vs 78.5%
p-value: p=<0.05
Circulating PCSK9 levels are elevated in women with stage III breast cancer compared to those with benign lesions and correlate with disease severity, suggesting a potential role for PCSK9 in tumor progression.
Limitations
- Small sample size
- Combination of benign disease with premalignant tumors to form a control group
- Lack of information on statins, other lipid-lowering drugs, hormonal replacement, and menopausal status
- Ethnical origins of women were not documented
- Small cohort of 46 women
- Insufficient power to detect changes in the lipid profile
- Study not designed to address the origin of the extra levels of PCSK9
Cite This Study
Chong et al. (2022) conducted a case-control in Breast cancer (n=46). Stage III breast cancer vs. Benign breast lesion was evaluated on Circulating PCSK9 levels (ng/mL) (p=<0.05). Circulating PCSK9 levels were significantly higher in women with stage III breast cancer compared to age-matched counterparts presenting a benign breast lesion (95.9 vs 78.5 ng/mL).
View Full Paper
Ask AI
Bookmark
Share